MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Aldeyra Therapeutics Inc

Open

2.6 2.77

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.51

Max

2.74

Belangrijke statistieken

By Trading Economics

Inkomsten

-696K

-16M

Verkoop

245K

245K

EPS

-0.27

Winstmarge

-6,465.066

Werknemers

9

EBITDA

-703K

-15M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+264.91% upside

Dividenden

By Dow Jones

Volgende Winsten

30 apr 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-227M

134M

Vorige openingsprijs

-0.17

Vorige sluitingsprijs

2.6

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Aldeyra Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 apr 2025, 22:40 UTC

Belangrijke Marktbewegers

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

18 nov 2024, 20:20 UTC

Belangrijke Marktbewegers

Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application

Peer Vergelijking

Prijswijziging

Aldeyra Therapeutics Inc Prognose

Koersdoel

By TipRanks

264.91% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 9.67 USD  264.91%

Hoogste 12 USD

Laagste 6 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Aldeyra Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technische score

By Trading Central

2.355 / N/ASteun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Very Strong Bearish Evidence

Lange Termijn

Strong Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.